Results 41 to 50 of about 876 (115)

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Favipiravir‐induced bradycardia: A case report

Clinical Case Reports
Key Clinical Message The purpose of this case report is to reveal one of the cardiovascular side effects of favipiravir, sinus bradycardia. Abstract Favipiravir has emerged as a potential treatment for COVID‐19, with its antiviral properties showing ...
Alireza Kashefizadeh, Laya Ohadi, Farbod Amiri, Maryam Abdolmaleki, Vahid Eslami, Mehrdad Jafari Fesharaki   +5 more
doaj   +1 more source

New insights into electronic and adsorption energies of metallofullerenes C19M

Results in Materials, 2023
A comprehensive electronic investigation was carried out by G09W program to provide new insights into the adsorption energies of metallofullerenes C19M (M = Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu and Zn). In this regard, the DFT calculations were performed on
A.A. El-Barbary, I.F.M. AL-Dosari
doaj   +1 more source

Chandipura Virus: An Emerging Neurological Threat Transmitted by Sandflies in India

Immunity, Inflammation and Disease, Volume 14, Issue 7, July 2026.
Chandipura virus (CHPV), a neurotropic arbovirus transmitted primarily by sandflies, has emerged as a significant public health concern in India following recurrent outbreaks with high pediatric fatality rates. This review highlights the virus's virology, transmission dynamics, clinical features, and the urgent need for improved diagnostics ...
Abrar Ahmad Zargar, Reena Gupta, P. Krishnamoorthy   +2 more
wiley   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Use of Favipiravir in Covid-19 Patients: A Narrative Review

JPSCR: Journal of Pharmaceutical Science and Clinical Research
COVID-19 is an acute respiratory disease resulting from the infection of SARS-COV-2 viruses and causes high morbidity, which requires appropriate treatment targets. Favipiravir is an antiviral that selectively inhibits RNA-dependent RNA polymerase (RdRp)
Vitarani Dwi Ananda Ningrum, Annisa Fitria, Fadiyah Ulfa Hanur   +2 more
doaj   +1 more source

A highly sensitive and green electroanalytical method for the determination of favipiravir in pharmaceutical and biological fluids

BMC Chemistry, 2023
Background Favipiravir is currently used for the treatment of coronavirus disease-2019 (COVID-19). Objective A highly sensitive and eco-friendly electroanalytical method was developed to quantify favipiravir.
Heba M. El-Sayed, Hisham Ezzat Abdellatef, Hassan A. M. Hendawy, Omar M El-Abassy, Hany Ibrahim   +4 more
doaj   +1 more source

Navigating the Future of Respiratory Infections: Key Insights From International Congress in Singapore, 17–20 September 2025

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil, Wilson Guo Wei Goh, Charlotte Zheng, Stephanie Sutjipto, Dorothy Hui Lin Ng, Maria Zambon   +5 more
wiley   +1 more source

A Sequence‐Based Update on Amino Acid Substitutions in Influenza Polymerase Acidic Protein in Europe That Alter Baloxavir Susceptibility From 2009 to 2025

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background Influenza causes 650,000 deaths, 3–5 million hospitalizations, and 1 billion cases worldwide each year. There is a limited repertoire of antivirals available to tackle this burden, highlighting the risk of developing resistance to current drugs.
Alejandro Martín‐Toribio, Inés Inchausti‐Moya, Marina Toquero‐Asensio, Sonia García‐Díaz, Javier Sanchez‐Martinez, Carla Rodriguez‐Crespo, Silvia Galindo‐Carretero, Raquel Iglesia‐Aparicio, Celia Lopez‐Gonzalo, Ana Antón‐Contreras, Silvia Rojo‐Rello, Marta Dominguez‐Gil, Marta Hernández, Jose M. Eiros, Estanislao Nistal‐Villan, Iván Sanz‐Muñoz   +15 more
wiley   +1 more source

Heart rate reduction during favipiravir therapy for hospitalized COVID-19 patients: experience from 6 cases

Journal of Hospital General Medicine, 2023
Favipiravir is an RNA polymerase inhibitor that was developed in Japan, and its antiviral effect is expected to be useful against coronavirus disease 2019 (COVID-19). We examined the therapeutic effect of favipiravir use for 6 patients with COVID-19.
Megumi Shimada, Sakurako Tajiri, Raisuke Nishiyama, Hiroyuki Kato, Hirotake Sugiyama, Tadashige Ikeda, Masako Sato, Eriko Goto, Kenzo Nishiya   +8 more
doaj   +1 more source